A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

NCT06492304 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

T Cell Lymphoma
B Cell Lymphoma
Acute Myeloid Leukemia

Interventions

BIOLOGICAL: CTX131

Sponsor

CRISPR Therapeutics